Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04873401 · ClinicalTrials.gov registry record · NA
Leveraging Social Networks to Increase COVID-19 Testing Uptake
A NA study of COVID-19 and Opioid Use, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- NA
- Development phase
- 498
- Enrollment target
- 1
- Study location
NCT04873401: Completed NA study of COVID-19 and Opioid Use, sponsored by New York State Psychiatric Institute.
NCT04873401 is a NA study of COVID-19 and Opioid Use that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 498 participants, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04873401, a NA study of COVID-19 and Opioid Use, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 498 participants
- Enrollment target
- 1
- Study location
Study Summary
This two-year project will adapt and conduct a trial examining the ability of two recruitment strategies, chain-referral and credible messenger, to reach those who use opioids and other substances in order to increase their uptake of onsite point of care COVID-19 testing that will be delivered in two community based organizations (CBOs): Alliance for Positive Change and Argus Health Inc. In Phase 1, Adapt two implementation strategies to support COVID-19 testing uptake and sustainability, adapting elements of existing efficacious social network-based interventions via a CBPR approach. In Phase 2, we will examine and compare the efficacy of two sets of implementation strategies on (i) reach, (ii) testing uptake, (iii) service delivery (i.e. quarantine, medical care, contact tracing) and (iv) sustainability for individuals who use opioids and other drugs. In Phase 3, Elucidate and compare the system/organizational-, staff-, and individual-level factors that influence implementation (i.e. fidelity, acceptability, feasibility, sustainability) of the strategies to develop a plan for dissemination and scale-up in other CBOs who serve opioid and other substance using individuals in NYC.
Primary Outcome
Number of participants who agreed to take a COVID-19 rapid test out of those who were enrolled (n=498)
Conditions Studied
Interventions
- BEHAVIORAL Chain-referral
- BEHAVIORAL Credible Messenger
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2023-01-01 |
| Phase | NA |
What the finished NCT04873401 record still lists
NCT04873401 is an interventional study that assigns participants to a tested intervention. The registered 498 participants enrollment target is mid-sized for trials with a published cap, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Chain-referral is the first listed.
NCT04873401 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04873401 about?
NCT04873401 is a clinical study titled "Leveraging Social Networks to Increase COVID-19 Testing Uptake". This two-year project will adapt and conduct a trial examining the ability of two recruitment strategies, chain-referral and credible messenger, to reach those who use opioids and other substances in order to increase their uptake of onsite point of care COVID-19 testing that will be delivered in tw...
What is the current status of trial NCT04873401?
This trial is currently completed. It is a NA study. The enrollment target is 498 participants. The study started on 2021-04-20. Estimated completion is 2023-01-01.
What conditions does trial NCT04873401 study?
This clinical trial studies the following conditions: COVID-19, Opioid Use, Substance Use.
What interventions are being tested in trial NCT04873401?
The interventions under investigation include: Chain-referral (BEHAVIORAL), Credible Messenger (BEHAVIORAL).
Who is sponsoring clinical trial NCT04873401?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04873401 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04873401's enrollment target sits among peer trials
498 114th of 298 higher than 185 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Music Mindfulness Study 2a.
RECRUITING · NA
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Evaluating the Impact of Social Music
RECRUITING · NA
-
The SINCERE Intervention to Address COVID-19 Health Disparities
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04137900 · 499 participants · Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- NCT06733480 · 499 participants · NA
Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI